The European Medicines Agency (EMA) has released its latest monthly update on pharmacovigilance regulatory recommendations for centrally authorized veterinary medicinal products. These updates, effective throughout 2025, highlight new safety measures and precautionary guidelines aimed at enhancing animal health and ensuring the efficacy of veterinary medicines across Europe.
Divence Penta: New Safety Measures Introduced
During the Committee for Veterinary Medicinal Products (CVMP) meeting held from May 13-15, 2025, significant revisions were made to the Summary of Product Characteristics (SPC) and Package Leaflet (PL) for Divence Penta. This bovine vaccine now explicitly lists injection site inflammation and elevated temperatures as very common side effects. Additionally, uncommon adverse reactions such as anaphylactic-type responses and decreases in milk production have been documented, urging veterinarians to monitor cattle closely post-vaccination.
Osurnia: Enhanced Precautions for Canine Health
The CVMP’s March 11-13, 2025 meeting introduced critical updates for Osurnia, a veterinary medicinal product containing Terbinafine, Florfenicol, and Betamethasone acetate. The revised guidelines emphasize the risk of ocular irritation in dogs, recommending immediate flushing with water and veterinary consultation if accidental eye contact occurs. Additionally, rare but severe eye disorders and hearing impairments have been reported, necessitating heightened vigilance and proactive management by pet owners and veterinarians alike.
• Increased monitoring of injection sites in cattle post-Divence Penta administration.
• Immediate veterinary intervention recommended for any signs of hypersensitivity in dogs using Osurnia.
• Enhanced training for veterinarians on recognizing and managing rare adverse reactions.
The EMA’s proactive approach in updating these guidelines underscores its commitment to animal welfare and public health. By meticulously evaluating post-authorization experiences, the agency ensures that veterinarians are equipped with the latest information to mitigate risks associated with veterinary medicinal products.
Veterinary professionals are advised to familiarize themselves with these updates to maintain compliance and uphold the highest standards of animal care. Pet owners should also stay informed about the potential side effects of treatments administered to their animals, fostering a collaborative effort in ensuring safe and effective veterinary care.
Implementing these regulatory recommendations not only enhances the safety profile of veterinary medicines but also reinforces trust between veterinarians, pet owners, and regulatory bodies. The EMA’s continuous monitoring and transparent communication play a pivotal role in advancing veterinary pharmacovigilance, ultimately contributing to healthier livestock and companion animals across Europe.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
